Updates are available Correction dated 2025-07-03
Click to view Correction: https://doi.org/10.1038/s41598-025-07762-4
-
Authors
Fantini, Jacques
Azzaz, Fodil
Aulas, Anaïs
Chahinian, Henri
Yahi, Nouara
-
Funding
Funding for this research was provided by:
AmyPore (Private funding)
- License Information
-
More Information
Article History
Received: 22 October 2024
Accepted: 12 March 2025
First Online: 17 March 2025
Change Date: 3 July 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-025-07762-4
Declarations
:
: N.Y. and J.F. are co-inventors of the AmyP53 peptide (patent Application EP15709163.8 A), currently under development for the treatment of Alzheimer’s and Parkinson’s diseases by the AmyPore company. H.C. is president of the Ethics and Scientific Committee of AmyPore. A.A. is the project leader of AmyPore. F.A. does not have any conflict of interest. All other authors have no competing interest.
